The Use Of An Anti-il2 Receptor Antibody In The Treatmen

这是一项Zenapax（一种人源抗tac抗体）与安慰剂联合标准疗法治疗白塞氏病眼部并发症的随机隐蔽性试点试验。该研究的主要目的是调查Zenapax在控制Behcet病患者眼部复发性表现的安全性和有效性。20名患者将被随机分配。该研究的主要疗效结果基于2年研究期间眼部发作的次数和免疫抑制药物的用量。次要疗效指标包括炎症水平。本研究继续积极招募患者。结果由NEI数据和安全监测委员会监测。由于这是一项正在进行的隐蔽性研究，因此没有结果报告。

This is a randomized masked pilot trial of Zenapax (a humanized anti-Tac antibody) vs placebo combined with standard therapy in the treatment of the ocular complications of Behcet's disease. The primary goal of the study is to investigate the safety and efficacy of Zenapax in controlling the recurrent explosive nature of ocular manifestations in patients with Behcet's disease. Twenty patients will be randomly assigned. The primary efficacy outcomes of the study are based on the number of ocular attacks experienced and the amount of immunosuppressive medications over the 2 year study period. Secondary efficacy outcomes include the level of inflammation. This study continues to actively recruit patients. The results are monitored by the NEI Data and Safety Monitoring Committee. Since it is an ongoing masked study, there are no results to report.